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Abstract
CLINICAL TRIALS - Human clinical trials are an important last hurdle in the development of new drugs and
therapies. Today, The Conversation takes a closer look at this vital scientific endeavour with three articles
that look at different aspects of the process.
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Ethics committees are the very bodies that ensure the safety
of clinical trials. Image from shutterstock.com

CLINICAL TRIALS – Human clinical trials are an important last hurdle in the development of
new drugs and therapies. Today, The Conversation takes a closer look at this vital scientific
endeavour with three articles that look at different aspects of the process.

Testing new drugs in clinical trials is a billion-dollar industry in Australia, with most of the
money coming from international pharmaceutical companies. But as investment grows in India,
China, and other emerging competitors, some people argue we need to make Australia more
attractive to such investment. One of their solutions is to water down the ethics approval
process.
Responding to these concerns, the Coalition’s election policy on medical research promises to
“move swiftly” with reforms to the ways in which clinical trials are conducted, by developing:
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a nationally consistent approach to ethical standards to reduce complexity, speed up
the process and where possible, rationalise the number of ethics committees to reduce the large number that currently exist.

Before major changes are introduced, however, it is important to remember that ethics
committees are the very bodies that ensure the safety of clinical trials and maintain public
confidence.
Developed in response to concerns about the untrammelled power of medical institutions in
the 1970s, as well as reports of egregious excesses by researchers in the United States and
elsewhere, the ethics committee system has become highly refined in both its processes and
in the substance of the issues it addresses.
In Australia, it is also remarkably devolved and democratic, drawing in thousands of men and
women from different walks of life across the country to engage in conversation, for no
personal gain, about ethical issues in health care and research.
Established by hospitals and universities, the panels review research proposals and ensure
they’re ethically acceptable. Their deliberations cover potential risks and benefits to both
individuals and the wider society and issues relating to consent, confidentiality, privacy,
conflicts of interest and protection of vulnerable participants.

Criticisms of the ethics committee system
Critics of the system complain about the time and expense involved in the ethics review
process and the added burdens it allegedly imposes on researchers and drug companies.
They argue that it creates delays, adds to costs and acts as a disincentive to investment.
They draw particular attention to alleged difficulties associated with obtaining approval for
multi-centre trials – that is, trials conducted at several sites simultaneously – because of
unnecessary duplication and frequent inconsistent outcomes.
It is generally concluded that all these problems would be solved by replacing the present
decentralised system with a centralised committee system that has authority to make decisions
for the entire country.
None of these criticisms is well founded and it is possible that the proposed solution may be
both counterproductive and inappropriate – particularly where research must take account of
local concerns, such as is the case with multi-site Indigenous health research.
In fact, the evidence shows ethics committees in Australia operate with remarkable efficiency,
with the time between submission and approval of a project often occurring in no more than a
few weeks.
And the ethics review process is generally concluded well in advance of other essential
organisational processes, such as legal approval, establishment of insurance policies, and
other governance decisions, including those concerning institutional commitments, staffing and
logistic issues.
Concerns over multi-centre trials may have once been well founded, but this is long past. A
single national application form has been in place for more than five years and there are
well-established coordinating mechanisms at both the state and national levels to allow unified
ethics review processes.
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In comparison with world standards, the system is economical and the times to approval are
comparable with best practice elsewhere in the world.

Ethics committees draw in thousands of men and women from
different walks of life. Flickr/TEDxKyoto

Global trends
Over the past 15 years, the number of new clinical trials approved in Australia has been
relatively static – not in decline as is sometimes claimed. But the reason for this has nothing to
do with ethics committees or the ethics review process.
Rather, approval of new trials reflects primarily the prevailing economic conditions – with a
predicable drop having occurred worldwide during the global financial crisis of 2008 to 2009 and the changing attractiveness of Australia in response to fluctuations in the value of the
dollar.
Most importantly, the development of a thriving clinical research capacity in India, China,
South-East Asia, Latin America, Brazil, Russia and Eastern Europe – many of which are
grappling with very similar problems - has meant that an increasing volume of work is being
undertaken in these countries. Indeed, the Australian experience has been mirrored almost
exactly by that of the United States and the European Union.

Retaining trust in clinical trials
So, would dismantling or watering down the ethics review system attract more research dollars
to Australia? This is highly unlikely. Not only would it have no impact on the factors mentioned
above but it’s likely to undermine the high levels of public trust and confidence on which
recruitment of patients for clinical studies critically depends.
The sense that essential protections are being weakened in order to increase investment
income may well cause irreparable damage to the status and prestige of clinical research in
this country.
This is not to say that the present system is perfect. Attempts to improve the efficiency of data
collection – such as electronic systems for collecting, processing and storing data – can help
to keep prices down as well as assist with monitoring and improving safety.
Recent initiatives to make it easier for members of the community to participate in clinical
research, such as ClinicalTrialsConnect, are welcome and will no doubt also improve the
efficiency of recruitment. But changes such as this will not reverse the large scale global
trends to which we are all subject.
We need to continue the debate about how to maximise research investment. But we can’t
lose sight of the great contribution the ethics committee process, and the men and women who
constitute it, makes to ensuring the safety of drug development and the continuing high status
of the research enterprise in Australia.
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Attempts to undermine or destroy the ethics committee system will ultimately be harmful to all
of us.
Click the links below for other articles in the package:
Looking back on the chequered past of drug trials
Care and consent: the fraught ethics of international clinical trials
And from our archives:
Clinical trials are useful – here’s how we can ensure they stay so
What Australia should do to ensure research integrity
Register all trials, report all results – it’s long overdue
Remove industry bias from clinical trials before it’s too late
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